Table 3.
Multivariable analysis of receipt of appropriate treatment according to patient and health care setting characteristics for adolescents and young adults with cancer (n = 354*)
| Characteristic | Adj. OR(95% CI) | P † |
|---|---|---|
| Age at initial diagnosis, y | .70 | |
| 15–19 | 1.0 (reference) | |
| 20–24 | 2.0 (0.8 to 5.1) | |
| 25–29 | 1.5 (0.7 to 3.5) | |
| 30–34 | 1.6 (0.6 to 4.0) | |
| 35–39 | 1.6 (0.7 to 4.0) | |
| Race/ethnicity | .10 | |
| Non-Hispanic white | 1.0 (reference) | |
| Hispanic | 2.0 (1.0 to 4.3) | |
| Non-Hispanic black | 2.5 (1.0 to 6.4) | |
| Other/unknown | 1.4 (0.6 to 3.2) | |
| Sex | .27 | |
| Male | 1.0 (reference) | |
| Female | 0.8 (0.5 to 1.2) | |
| Insurance source | .40 | |
| Private | 1.0 (reference) | |
| Public | 0.8 (0.4 to 1.4) | |
| Annual median household income in census tract at diagnosis (quartiles) | .48 | |
| Q1 (≤$40K) | 1.0 (reference) | |
| Q2 (>$40K – $54K) | 0.9 (0.4 to 1.8) | |
| Q3 (>$54K – $72K) | 1.5 (0.7 to 3.1) | |
| Q4 (>$72K) | 1.4 (0.7 to 3.1) | |
| Hospital (initial treatment) | .16 | |
| NCI-designated cancer center | 1.0 (reference) | |
| Academic institution | 0.7 (0.2 to 2.6) | |
| Cancer center, NOS | 0.5 (0.2 to 1.0) | |
| Community hospital | 1.0 (0.4 to 2.5) | |
| Clinical trial participation|| | .04 | |
| No or not recorded in med. record | 1.0 (reference) | |
| Yes | 2.6 (1.1 to 6.4) | |
| Summary stage at diagnosis | .92 | |
| Local | 1.0 (reference) | |
| Regional | 1.0 0.5 to 2.0 | |
| Distant | 1.1 0.6 to 2.2 | |
| Surveillance, epidemiology and end results region | .45 | |
| San Francisco Bay area | 1.0 (reference) | |
| Los Angeles | 1.1 (0.3 to 3.9) | |
| Greater California | 2.2 (0.7 to 6.3) | |
| Detroit Metropolitan area | 3.0 (1.1 to 8.3) | |
| Iowa | 1.9 (0.6 to 5.9) | |
| Seattle-Puget Sound area | 2.3 (0.9 to 5.8) | |
| Louisiana | 1.4 (0.5 to 3.8) | |
| Cancer type | =<.01 | |
| Hodgkin lymphoma | 1.0 (reference) | |
| Acute lymphoblastic leukemia | 0.6 (0.2 to 1.8) | |
| Germ cell cancer* | 3.2 (1.5 to 7.1) | |
| Non-Hodgkin’s lymphoma | 2.2 (1.1 to 4.1) | |
| Sarcoma | 2.8 (0.9 to 8.9) |
* Excludes 116 testis patients with Tumor, Node, Metastases Stages I, T1, or T2 cancer, and another 34 patients with missing or unknown stage, insurance status, or hospital type. NCI = National Cancer Institute; NOS = non-NCI designated.
† P values are derived from two-sided likelihood ratio tests of the significance of the estimated coefficient (expressed as an adjusted odds ratio) for each variable as a whole, adjusting for all other variables in the table.
|| Derived from combination of self-report and medical record review.